SHARON BIO-MEDICINE LTD.

NSE : SHARONBIOBSE : 532908ISIN CODE : INE028B01029Industry : Pharmaceuticals & DrugsHouse : Private
BSE3.210 (0 %)
PREV CLOSE ( ) 3.21
OPEN PRICE ( ) 3.26
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 32550
TODAY'S LOW / HIGH ( )3.10 3.30
52 WK LOW / HIGH ( )3.1 4.65
NSE3.300 (0 %)
PREV CLOSE( ) 3.30
OPEN PRICE ( ) 3.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 8834
TODAY'S LOW / HIGH( ) 3.30 3.30
52 WK LOW / HIGH ( )2.95 4.5
( in Million)
Select year
ParticularsMar2016Jun2015Jun2014Jun2013Jun2012
Profit Before Tax-2178.93-1446.09854.59670.38542.10
Adjustment29.88224.52589.48416.17324.17
Changes In working Capital2543.991323.05-1554.02-1363.24-1060.70
Cash Flow after changes in Working Capital394.94101.48-109.94-276.68-194.44
Cash Flow from Operating Activities-314.88-834.98-696.24-704.43-534.29
Cash Flow from Investing Activities-5.05-100.60-271.23-639.77-609.73
Cash Flow from Financing Activities262.24971.401027.731344.261168.48
Net Cash Inflow / Outflow-57.6935.8260.250.0624.45
Opening Cash & Cash Equivalents159.25123.4363.1863.1238.67
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANANANA
Effect of Foreign Exchange FluctuationsNANANANANA
Closing Cash & Cash Equivalent101.56159.25123.4363.1863.12

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.